Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...

Wedbush has a “Outperform” rating and a $40.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Get AnaptysBio alerts: ...

International Business Machines Co. (NYSE:IBM – Free Report) – Equities research analysts at Wedbush issued their FY2025 earnings estimates for shares of International Business Machines in a ...

Fintel reports that on February 7, 2025, Wedbush upgraded their outlook for Spectrum Brands Holdings (NYSE:SPB) from Neutral ...

Wedbush highlights Palantir and Salesforce as top AI investments, predicting rapid enterprise adoption and major capital ...

Fintel reports that on February 6, 2025, Wedbush initiated coverage of Bicara Therapeutics (NasdaqGM:BCAX) with a Outperform ...

According to 4.5-star Wedbush Securities analyst Dan Ives, the broader software industry is now set to benefit from the exploding use cases of ...

Looking ahead, IDC estimates AI platform sales will increase at 40% annually to reach $153 billion by 2028. Palantir ...

Super Micro Computer shares surged Wednesday after the company offered a strong sales outlook for 2026 on demand for AI servers and said it expects to submit its delayed regulatory filings in time to ...

Wedbush views the unsolicited $97.4B bid by a group led by Elon Musk for the non-profit that controls OpenAI, aimed to slow down the startup's capital raising process.

Wedbush said Palantir Technologies (PLTR) and Salesforce (CRM) remain the two best software plays on the AI Revolution for 2025.